查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1943164

異種移植市場－全球產業規模、佔有率、趨勢、機會及預測（依動物類型、異種產品、器官、最終用戶、地區及競爭格局分類，2021-2031年）

Xenotransplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Xeno Products, By Organs, By End Users, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球異種移植市場預計將經歷強勁成長，預計從 2025 年的 157.3 億美元成長到 2031 年的 265.4 億美元，複合年成長率為 9.11%。

這個領域涉及將源自非人類動物的活細胞、組織或器官移植、植入或輸注到人類受體。推動該市場發展的關鍵因素是器官移植需求旺盛而人類捐贈者器官短缺之間的巨大缺口，以及基因工程技術的進步如何緩解免疫不相容問題。根據器官捐贈與移植聯盟的數據，2024年全球僅進行了172,397例固態器官移植手術，凸顯了器官嚴重短缺的現狀，也因此亟需這些替代治療方案。

市場概覽
預測期 2027-2031
市場規模：2025年 157.3億美元
市場規模：2031年 265.4億美元
複合年成長率：2026-2031年 9.11%
成長最快的細分市場 腎
最大的市場 北美洲

阻礙市場擴張的一大障礙是人畜共通傳染病的風險，即感染疾病感染疾病動物通用傳播給人類患者。這項安全隱患要求嚴格的篩檢程序和監管，可能會延緩異種移植產品的核准流程和商業化進程。因此，儘管這項技術有潛力滿足對器官的迫切需求，但要成功推向市場，仍需進行廣泛的安全檢驗以防止跨物種傳播，這是該行業必須克服的關鍵挑戰。

市場促進因素

全球持續存在的人類器官短缺是異種移植領域發展的主要驅動力。這是由於可用器官數量與等待移植的患者人數之間的差距日益擴大所致。可用的人類器官短缺迫切需要研究非人類替代器官，以防止等待移植的患者死亡。例如，美國衛生資源和服務管理局 (HRSA) 在 2024 年 3 月報告稱，僅在美國國家器官移植等待名單上就有超過 10.3 萬人。這一巨大的缺口凸顯了開發可擴展解決方案（例如異種移植）的迫切需求，以幫助那些在無法及時找到匹配的人類捐贈者的情況下，患有終末期器官衰竭的患者。

此外，基因編輯和基因工程技術的進步正在加速市場成長，因為它們克服了以往阻礙成功的免疫學障礙。例如，CRISPR-Cas9技術使科學家能夠修改豬的基因組，去除導致超急性排斥反應的抗原，並插入人類基因以提高相容性。一個典型的例子是，2024年3月在麻省總醫院進行的全球首例基因編輯豬腎移植手術，手術涉及69處基因組編輯。這些方法的商業性可行性也得到了大量資金的支持，例如eGenesis在2024年獲得的1.91億美元D輪資金籌措，用於推進其異種移植產品線進入臨床試驗階段。

市場挑戰

通用感染疾病，特別是動物供體向人類受體傳播病原體的風險，構成了阻礙全球異種移植市場成長的主要障礙。這項安全問題促使監管機構強制要求實施嚴格的預防措施，例如建立生物安全養殖設施，並對豬內源性逆轉錄病毒等病原體進行徹底篩檢。這些嚴格的要求顯著增加了研發的複雜性和成本，延長了臨床試驗週期，並延緩了異種移植產品從試驗階段轉化為商業性化治療方法的影響。

此外，由於無法快速檢驗安全標準，阻礙了企業擴張以滿足器官移植的巨大且迫切的需求，導致很大一部分潛在市場尚未開發。這套頸部阻礙了能夠彌合供需缺口的技術的廣泛應用。正如美國器官共享聯合網路（UNOS）在2024年指出的那樣，美國有超過10萬人處於器官移植等待名單上，但僅進行了48149例移植手術。這種差距凸顯了巨大的市場機會仍未得到充分利用，這主要是由於通用感染疾病安全方面的挑戰尚未解決，以及監管機構因此而採取的謹慎態度。

市場趨勢

該領域的一個關鍵轉折點是從臨床前研究和零星的仿單標示外用藥案例過渡到結構化的、經監管機構核准的「首次人體臨床試驗」。這一轉變標誌著該行業在收集生技藥品核准申請所需的標準化安全性和有效性數據方面取得了進展，從而建立了一條清晰的商業性核准路徑，並證明了基因編輯器官生產的可擴展性。例如，聯合治療公司（United Therapeutics）於2025年2月宣布，其臨床實驗申請（IND）已獲得美國食品藥物管理局（FDA）的核准，可以招募其UKidney異種移植臨床試驗的首批六名患者。

同時，腎臟異種移植的商業性化已成為一項重要的策略重點，各公司紛紛將目光投向腎臟病領域。這是因為與心臟或肝臟手術相比，透析作為一種替代療法，可以降低移植失敗導致的近期死亡風險。儘管透析起到了一定的安全保障作用，但其限制也進一步凸顯了此適應症的緊迫性。 2025年9月，在EGEN-2784獲得IND核准後，eGenesis公司報告稱，透析患者的五年死亡率超過50%。這項數據凸顯了市場對一種可行的異種移植替代方案的迫切需求，該方案能夠彌補現有腎臟替代療法的不足。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球異種移植市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依動物種類（豬、兔子、狒狒等）
    • 異種移植產品（器官、組織、細胞）
    • 依器官分類（腎臟、肝臟、心臟、角膜等）
    • 按最終使用者（移植中心、醫院等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美異種移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲異種移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區異種移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲異種移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲異種移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球異種移植市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • United Therapeutics Corporation
  • eGenesis, Inc.
  • Novartis AG
  • Astellas Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Preservation Solutions, Inc.
  • OrganOX Limited
  • TransMedic, Pte. Ltd.
  • Pfizer, Inc.
  • Makana Therapeutics

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 10660

The Global Xenotransplantation Market is projected to experience robust growth, expanding from a valuation of USD 15.73 Billion in 2025 to USD 26.54 Billion by 2031 at a compound annual growth rate of 9.11%. This sector encompasses the transplantation, implantation, or infusion of live cells, tissues, or organs derived from nonhuman animal sources into human recipients. The market is primarily driven by the critical gap between the high demand for organ replacements and the scarce supply of human donors, alongside breakthroughs in genetic engineering that mitigate immune incompatibility. Data from the Organ Donation and Transplantation Alliance in 2024 indicated that only 172,397 solid organ transplants were conducted globally, underscoring the severe shortage that necessitates these alternative therapeutic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 15.73 Billion
Market Size 2031USD 26.54 Billion
CAGR 2026-20319.11%
Fastest Growing SegmentKidney
Largest MarketNorth America

One significant obstacle potentially hindering market expansion is the risk of zoonosis, which entails the transmission of infectious diseases from animal hosts to human patients. This safety concern mandates rigorous screening protocols and strict regulatory oversight, which can delay the approval processes and commercial availability of xenotransplantation products. Consequently, while the technology promises to address the urgent need for organs, the requirement for extensive safety validation to prevent cross-species infection remains a critical challenge that the industry must navigate to ensure successful market adoption.

Market Driver

The persistent global shortage of human donor organs acts as the primary catalyst for the xenotransplantation sector, fueled by the widening disparity between available organs and the growing number of patients on waiting lists. This unavailability of viable human organs necessitates urgent research into nonhuman alternatives to prevent mortality among patients waiting for transplants; for instance, the Health Resources and Services Administration reported in March 2024 that over 103,000 individuals were on the U.S. national transplant waiting list alone. This substantial gap highlights the critical need for scalable solutions like xenotransplantation to support patients suffering from end-stage organ failure who are unable to secure human donor matches in a timely manner.

Additionally, advancements in gene editing and genetic engineering technologies are accelerating market growth by overcoming the immunological barriers that have historically prevented successful cross-species transplantation. Technologies such as CRISPR-Cas9 enable scientists to modify porcine genomes by removing antigens that trigger hyperacute rejection and inserting human genes to enhance compatibility, as demonstrated by Massachusetts General Hospital's March 2024 report on the first genetically edited pig kidney transplant featuring 69 genomic edits. The commercial viability of these procedures is further supported by significant financial investment, exemplified by eGenesis securing $191 million in Series D financing in 2024 to advance their xenotransplantation pipeline toward clinical trials.

Market Challenge

The risk of zoonosis, specifically the potential transmission of infectious agents from animal donors to human recipients, presents a formidable barrier that directly impedes the growth of the Global Xenotransplantation Market. This safety issue compels regulatory bodies to enforce stringent precautionary measures, such as the requirement for biosecure breeding facilities and exhaustive screening for pathogens like porcine endogenous retroviruses. These rigorous demands significantly increase the complexity and cost of research and development, thereby extending the timeline for clinical trials and delaying the transition of xenotransplantation products from experimental stages to commercially viable therapies.

Furthermore, the inability to rapidly validate safety standards prevents the industry from scaling operations to meet the massive and immediate demand for organ replacement, leaving a large portion of the addressable market unserved. This bottleneck hinders the technology from bridging the gap between supply and demand; as noted by the United Network for Organ Sharing in 2024, more than 100,000 candidates remained on the U.S. waiting list while only 48,149 transplants were performed. This disparity underscores a substantial market opportunity that remains inaccessible largely due to unresolved challenges regarding zoonotic safety and the resulting regulatory hesitation.

Market Trends

A pivotal shift in the sector is the transition from preclinical studies and sporadic compassionate-use cases to structured, regulatory-approved First-in-Human Clinical Trials. This trend signifies the industry's progression toward gathering the standardized safety and efficacy data necessary for Biologics License Applications, creating a clear pathway for commercial approval and validating the manufacturing scalability of gene-edited organs. Illustrating this progress, United Therapeutics announced in February 2025 that it received FDA clearance for its Investigational New Drug Application to enroll an initial cohort of six patients in the UKidney Xenotransplantation Clinical Trial.

Concurrently, the commercial prioritization of xenogeneic kidney transplantation has emerged as a dominant strategic focus, with companies concentrating on renal indications because dialysis serves as a fallback therapy that mitigates the immediate lethal risks associated with graft failure compared to heart or liver procedures. Despite dialysis acting as a safety net, its limitations continue to drive the urgent pursuit of this application; eGenesis reported in September 2025, upon receiving IND clearance for EGEN-2784, that the five-year mortality rate for dialysis exceeds 50%. This statistic emphasizes the critical market necessity for viable xenogeneic alternatives to address the shortcomings of current renal replacement therapies.

Key Market Players

  • United Therapeutics Corporation
  • eGenesis, Inc.
  • Novartis AG
  • Astellas Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Preservation Solutions, Inc.
  • OrganOX Limited
  • TransMedic, Pte. Ltd.
  • Pfizer, Inc.
  • Makana Therapeutics

Report Scope

In this report, the Global Xenotransplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xenotransplantation Market, By Animal Type

  • Pig
  • Rabbit
  • Baboon
  • Others

Xenotransplantation Market, By Xeno Products

  • Organs
  • Tissues
  • Cells

Xenotransplantation Market, By Organs

  • Kidney
  • Liver
  • Heart
  • Cornea
  • Others

Xenotransplantation Market, By End Users

  • Transplants Center
  • Hospitals
  • Others

Xenotransplantation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xenotransplantation Market.

Available Customizations:

Global Xenotransplantation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xenotransplantation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Pig, Rabbit, Baboon, Others)
    • 5.2.2. By Xeno Products (Organs, Tissues, Cells)
    • 5.2.3. By Organs (Kidney, Liver, Heart, Cornea, Others)
    • 5.2.4. By End Users (Transplants Center, Hospitals, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Xenotransplantation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Xeno Products
    • 6.2.3. By Organs
    • 6.2.4. By End Users
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Xenotransplantation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Xeno Products
        • 6.3.1.2.3. By Organs
        • 6.3.1.2.4. By End Users
    • 6.3.2. Canada Xenotransplantation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Xeno Products
        • 6.3.2.2.3. By Organs
        • 6.3.2.2.4. By End Users
    • 6.3.3. Mexico Xenotransplantation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Xeno Products
        • 6.3.3.2.3. By Organs
        • 6.3.3.2.4. By End Users

7. Europe Xenotransplantation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Xeno Products
    • 7.2.3. By Organs
    • 7.2.4. By End Users
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Xenotransplantation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Xeno Products
        • 7.3.1.2.3. By Organs
        • 7.3.1.2.4. By End Users
    • 7.3.2. France Xenotransplantation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Xeno Products
        • 7.3.2.2.3. By Organs
        • 7.3.2.2.4. By End Users
    • 7.3.3. United Kingdom Xenotransplantation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Xeno Products
        • 7.3.3.2.3. By Organs
        • 7.3.3.2.4. By End Users
    • 7.3.4. Italy Xenotransplantation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Xeno Products
        • 7.3.4.2.3. By Organs
        • 7.3.4.2.4. By End Users
    • 7.3.5. Spain Xenotransplantation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Xeno Products
        • 7.3.5.2.3. By Organs
        • 7.3.5.2.4. By End Users

8. Asia Pacific Xenotransplantation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Xeno Products
    • 8.2.3. By Organs
    • 8.2.4. By End Users
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Xenotransplantation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Xeno Products
        • 8.3.1.2.3. By Organs
        • 8.3.1.2.4. By End Users
    • 8.3.2. India Xenotransplantation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Xeno Products
        • 8.3.2.2.3. By Organs
        • 8.3.2.2.4. By End Users
    • 8.3.3. Japan Xenotransplantation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Xeno Products
        • 8.3.3.2.3. By Organs
        • 8.3.3.2.4. By End Users
    • 8.3.4. South Korea Xenotransplantation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Xeno Products
        • 8.3.4.2.3. By Organs
        • 8.3.4.2.4. By End Users
    • 8.3.5. Australia Xenotransplantation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Xeno Products
        • 8.3.5.2.3. By Organs
        • 8.3.5.2.4. By End Users

9. Middle East & Africa Xenotransplantation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Xeno Products
    • 9.2.3. By Organs
    • 9.2.4. By End Users
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Xenotransplantation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Xeno Products
        • 9.3.1.2.3. By Organs
        • 9.3.1.2.4. By End Users
    • 9.3.2. UAE Xenotransplantation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Xeno Products
        • 9.3.2.2.3. By Organs
        • 9.3.2.2.4. By End Users
    • 9.3.3. South Africa Xenotransplantation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Xeno Products
        • 9.3.3.2.3. By Organs
        • 9.3.3.2.4. By End Users

10. South America Xenotransplantation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Xeno Products
    • 10.2.3. By Organs
    • 10.2.4. By End Users
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Xenotransplantation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Xeno Products
        • 10.3.1.2.3. By Organs
        • 10.3.1.2.4. By End Users
    • 10.3.2. Colombia Xenotransplantation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Xeno Products
        • 10.3.2.2.3. By Organs
        • 10.3.2.2.4. By End Users
    • 10.3.3. Argentina Xenotransplantation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Xeno Products
        • 10.3.3.2.3. By Organs
        • 10.3.3.2.4. By End Users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Xenotransplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. United Therapeutics Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. eGenesis, Inc.
  • 15.3. Novartis AG
  • 15.4. Astellas Pharma, Inc.
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Preservation Solutions, Inc.
  • 15.7. OrganOX Limited
  • 15.8. TransMedic, Pte. Ltd.
  • 15.9. Pfizer, Inc.
  • 15.10. Makana Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer